Palvella Therapeutics (PVLA) grants 64,318 stock options to CSO Martini

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. disclosed that its Chief Scientific Officer, Jeffrey S. Martini, received a stock option grant. On February 5, 2026, he was awarded options to purchase 64,318 shares of common stock at an exercise price of $76.43 per share, granted for no cash cost.

The option vests in equal monthly installments over 48 months, beginning February 5, 2026, and each vesting installment requires his continuous service through the applicable vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Martini Jeffrey S

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	64,318	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 64,318 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martini Jeffrey S

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.43	02/05/2026		A		64,318		(1)	02/05/2036	Common Stock	64,318	$0	64,318	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVLA report for Jeffrey S. Martini?

Palvella Therapeutics reported a stock option grant to Chief Scientific Officer Jeffrey S. Martini. On February 5, 2026, he received options to purchase 64,318 shares of common stock at an exercise price of $76.43 per share, awarded at no cash cost.

How many Palvella Therapeutics (PVLA) options were granted in this Form 4?

The Form 4 shows a grant of stock options covering 64,318 shares of Palvella Therapeutics common stock. These options are derivative securities giving the right to buy shares at a fixed exercise price specified as $76.43 per share in the filing.

What is the vesting schedule for Jeffrey S. Martini’s PVLA stock options?

The options vest in equal monthly installments over 48 months starting February 5, 2026. Each monthly vesting installment requires Jeffrey S. Martini to remain in continuous service with Palvella Therapeutics through the applicable vesting date described in the filing.

What is the exercise price of the Palvella Therapeutics options granted?

The stock options granted to Jeffrey S. Martini carry an exercise price of $76.43 per share. This means he can purchase Palvella Therapeutics common stock at $76.43 for each of the 64,318 option shares, subject to vesting and other plan terms.

When do Jeffrey S. Martini’s PVLA stock options expire?

The Form 4 states that the stock options expire on February 5, 2036. Martini may exercise vested portions of the 64,318-share option grant until that expiration date, assuming he continues to satisfy the service-based vesting conditions.

Does Jeffrey S. Martini hold these Palvella options directly or indirectly?

The filing classifies the ownership of the 64,318 stock options as direct. The ownership form column shows “D,” indicating that Jeffrey S. Martini directly holds the derivative securities reported in this Form 4 submission.